Solid tumors are generally considered more difficult to treat than blood cancers. For example, chimeric antigen receptor T-cell (CAR-T) therapy has been amazingly effective against blood cancers that failed to respond to other types of treatment, while inroads against...
The first (and so far, only) chimeric antigen receptor T-cell (CAR-T) therapies—Kymriah (Novartis; Basel, Switzerland) and Yescarta—(Gilead; Foster City, CA) were approved in 2017, and remain one of the hottest immunotherapies on the market today. They work by...
The Elusive Cancer Vaccine Like unicorns, the fountain of youth and calorie-free chocolate, cancer vaccines have long proven elusive. But the emergence of a new crop of biotech companies makes it clear that a cancer vaccine is no myth. The latest advances in genomics...
Autoimmune Disorders: A Story Of Betrayal “Et tu, Brute?” The famous line spoken by Shakespeare’s Julius Caesar is synonymous with unexpected betrayal by a close friend. A once trusted member of the inner circle, Marcus Brutus joined the coup and turned on Caesar. The...
Ebola Finally Meets Its Match The headlining Ebola crisis of last summer devastated West Africa, marking the largest outbreak since the discovery of the disease in 1976. The glaring lack of a treatment or vaccine caused the virus to quickly spread within Guinea,...
From startups to the Fortune 500, we train employees at companies of all sizes. We offer customized, in-house courses and open enrollment classes. Visit Biotech Primer for more information.
